{"drugs":["Cardizem","Cardizem CD","Cartia XT","Dilacor XR","Dilt-CD","Dilt-XR","Diltia XT","Diltiazem Hydrochloride","Tiazac"],"mono":{"0":{"id":"180873-s-0","title":"Generic Names","mono":"Diltiazem Hydrochloride"},"1":{"id":"180873-s-1","title":"Dosing and Indications","sub":[{"id":"180873-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Atrial arrhythmia:<\/b> (IV bolus), initial 0.25 mg\/kg (or 20 mg) IV over 2 min; if inadequate response, may give second bolus 0.35 mg\/kg (25 mg) after 15 min<\/li><li><b>Atrial arrhythmia:<\/b> (IV continuous infusion), initial 5-10 mg\/hr; increase in 5 mg\/hr increments up to 15 mg\/hr maintained for up to 24 hr<\/li><li><b>Hypertension:<\/b> (extended release capsule; Cardizem(R) CD, Cartia XT(R), Dilt-CD(R)) initial, 120 to 240 mg ORALLY once daily; usual dose, 240 to 360 mg ORALLY once daily, up to 480 mg\/day<\/li><li><b>Hypertension:<\/b> (extended-release capsule; Dilacor XR(R), Diltia XT(R)) initial, 120 to 240 mg ORALLY once daily in the AM on an empty stomach; usual dose, 180 to 480 mg ORALLY once daily; MAX 540 mg\/day<\/li><li><b>Hypertension:<\/b> (extended release capsule; Tiazac(R), Diltzac(R), Taztia XT(R)) initial, 120 to 240 mg ORALLY once daily; usual dose 120 up to 540 mg once daily<\/li><li><b>Hypertension:<\/b> (extended release tablet; Cardizem(R) LA, Matzim(R) LA) initial, 180 to 240 mg ORALLY once daily; dose range, 120 to 540 once daily; MAX 540 mg\/day<\/li><li><b>Paroxysmal supraventricular tachycardia:<\/b> (IV bolus), initial 0.25 mg\/kg (or 20 mg) IV over 2 min; if inadequate response, may give second bolus 0.35 mg\/kg (25 mg) after 15 min<\/li><li><b>Paroxysmal supraventricular tachycardia:<\/b> (IV continuous infusion), initial 5-10 mg\/hr; increase in 5 mg\/hr increments up to 15 mg\/hr maintained for up to 24 hr<\/li><li><b>Stable angina, chronic:<\/b> (regular release tablet), initial 30 mg ORALLY 4 times daily before meals and at bedtime; usual dose 180 to 360 mg ORALLY daily, MAX 360 mg daily; titrate over 7 to 14 days, if required<\/li><li><b>Stable angina, chronic:<\/b> (extended release capsule; Cardizem(R) CD, Cartia XT(R), Dilt-CD(R)) initial, 120 to 180 mg ORALLY once daily up to 480 mg once daily<\/li><li><b>Stable angina, chronic:<\/b> (extended release capsule; Dilacor XR(R), Diltia XT(R)) initial, 120 mg ORALLY once daily in the AM on an empty stomach; titrate over 7 to 14 days, if required; usual dose 120 to 480 mg once daily<\/li><li><b>Stable angina, chronic:<\/b> (extended release capsule; Tiazac(R), Diltzac(R), Taztia XT(R)) initial, 120 to 180 mg ORALLY once daily up to 540 mg once daily; titrate over 7 to 14 days, if required<\/li><li><b>Stable angina, chronic:<\/b> (extended release tablet; Cardizem(R) LA, Matzim(R) LA), initial 180 mg ORALLY once daily; titrate over 7 to 14 days if required; usual dose 180 to 360 mg ORALLY once daily<\/li><\/ul>"},{"id":"180873-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness not established in children<\/li><li><b>Hypertension:<\/b> (TAB, regular release): 1.5 to 2 mg\/kg ORALLY daily in 3 to 4 divided doses; MAX 3.5 mg\/kg daily has been used<\/li><\/ul>"},{"id":"180873-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>liver disease:<\/b> dose reductions may be needed due to extensive hepatic metabolism<\/li><li><b>concomitant administration with simvastatin:<\/b> limit daily dose to simvastatin 10 mg and diltiazem 240 mg<\/li><\/ul>"},{"id":"180873-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Atrial arrhythmia<\/li><li>Hypertension<\/li><li>Paroxysmal supraventricular tachycardia<\/li><li>Stable angina, chronic<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Anal fissure<\/li><li>Coronary artery bypass graft<\/li><li>Diabetic nephropathy<\/li><li>Disorder related to transplantation<\/li><li>Hypertension, Perioperative<\/li><li>Myocardial infarction<\/li><li>Unstable angina<\/li><li>Variant angina<\/li><li>Ventricular arrhythmia<\/li><\/ul>"}]},"3":{"id":"180873-s-3","title":"Contraindications\/Warnings","sub":[{"id":"180873-s-3-9","title":"Contraindications","mono":"<ul><li>acute MI with pulmonary congestion on x-ray<\/li><li>administration of IV beta-blockers within a few hours of IV diltiazem<\/li><li>atrial fibrillation or flutter associated with an accessory bypass tract (Wolff-Parkinson-White or short PR syndromes); risk of potentially fatal heart rate fluctuations<\/li><li>cardiogenic shock<\/li><li>heart block, second or third-degree atrioventricular without a functioning ventricular pacemaker<\/li><li>hypersensitivity to diltiazem<\/li><li>newborns; some IV injections contain benzyl alcohol<\/li><li>sick sinus syndrome without a functioning ventricular pacemaker<\/li><li>symptomatic hypotension, systolic blood pressure 90 mmHg or less<\/li><li>ventricular tachycardia; may lead to hemodynamic deterioration and ventricular fibrillation<\/li><\/ul>"},{"id":"180873-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- supraventricular arrhythmias with hemodynamic compromise upon IV administration<\/li><li>-- use caution in patients with impaired ventricular function since worsening congestive heart failure has been reported<\/li><li>-- hypotension<\/li><li>Dermatologic:<\/li><li>-- dermatologic reactions leading to erythema multiforme or exfoliative dermatitis have been reported<\/li><li>Hepatic:<\/li><li>-- use caution in patients with hepatic impairment due to increased risk of toxicity<\/li><li>Renal:<\/li><li>-- use caution in patients with renal impairment due to increased risk of toxicity<\/li><li>Concomitant use:<\/li><li>-- avoid concurrent IV administration with drugs known to decrease peripheral resistance, intravascular volume, or myocardial contractility or conduction<\/li><li>-- avoid concurrent oral therapy with beta blockers or digitalis due to additive effect on heart rate<\/li><\/ul>"},{"id":"180873-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Diltiazem: C (FDA)<\/li><li>Diltiazem: C (AUS)<\/li><\/ul>"},{"id":"180873-s-3-12","title":"Breast Feeding","mono":"<ul><li>Diltiazem: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Diltiazem: WHO: WHO documentation states insufficient data.<\/li><li>Diltiazem: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"180873-s-4","title":"Drug Interactions","sub":[{"id":"180873-s-4-13","title":"Contraindicated","mono":"<ul><li>Cisapride (probable)<\/li><li>Colchicine (established)<\/li><li>Lomitapide (theoretical)<\/li><\/ul>"},{"id":"180873-s-4-14","title":"Major","mono":"<ul><li>Acebutolol (probable)<\/li><li>Afatinib (theoretical)<\/li><li>Alprenolol (probable)<\/li><li>Amiodarone (probable)<\/li><li>Apixaban (theoretical)<\/li><li>Aprepitant (probable)<\/li><li>Aripiprazole (theoretical)<\/li><li>Atazanavir (established)<\/li><li>Atenolol (probable)<\/li><li>Atorvastatin (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bosutinib (theoretical)<\/li><li>Bucindolol (probable)<\/li><li>Carbamazepine (theoretical)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Clarithromycin (established)<\/li><li>Clonidine (theoretical)<\/li><li>Clopidogrel (established)<\/li><li>Clozapine (established)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dantrolene (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dilevalol (probable)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (theoretical)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Dronedarone (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Erythromycin (probable)<\/li><li>Esmolol (probable)<\/li><li>Everolimus (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Ibrutinib (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Labetalol (probable)<\/li><li>Lacosamide (theoretical)<\/li><li>Levobunolol (probable)<\/li><li>Lovastatin (established)<\/li><li>Lurasidone (probable)<\/li><li>Mepindolol (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metoprolol (probable)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Nadolol (probable)<\/li><li>Naloxegol (theoretical)<\/li><li>Nebivolol (probable)<\/li><li>Nilotinib (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Oxprenolol (probable)<\/li><li>Paritaprevir (theoretical)<\/li><li>Penbutolol (probable)<\/li><li>Pindolol (probable)<\/li><li>Piperaquine (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Propranolol (probable)<\/li><li>Ranolazine (probable)<\/li><li>Romidepsin (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Simvastatin (established)<\/li><li>Sotalol (probable)<\/li><li>St John's Wort (theoretical)<\/li><li>Talinolol (probable)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolvaptan (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><\/ul>"},{"id":"180873-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Alfentanil (established)<\/li><li>Alfuzosin (probable)<\/li><li>Amlodipine (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Buspirone (probable)<\/li><li>Celecoxib (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Cimetidine (probable)<\/li><li>Clonixin (probable)<\/li><li>Colestipol (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Dalfopristin (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Digitoxin (probable)<\/li><li>Digoxin (probable)<\/li><li>Dipyrone (probable)<\/li><li>Dutasteride (probable)<\/li><li>Efavirenz (established)<\/li><li>Enflurane (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Fosaprepitant (established)<\/li><li>Fosphenytoin (probable)<\/li><li>Guggul (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Indinavir (probable)<\/li><li>Indomethacin (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lithium (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Methylprednisolone (probable)<\/li><li>Midazolam (probable)<\/li><li>Moricizine (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Nevirapine (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Phenytoin (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Quinupristin (probable)<\/li><li>Rifampin (probable)<\/li><li>Rifapentine (probable)<\/li><li>Ritonavir (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sirolimus (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Sulindac (probable)<\/li><li>Tacrolimus (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Triazolam (probable)<\/li><li>Valdecoxib (probable)<\/li><\/ul>"}]},"5":{"id":"180873-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia (1.7% to 3.6%), Peripheral edema (4.6% to 8%)<\/li><li><b>Neurologic:<\/b>Dizziness (3.5% to 6.4%), Headache (4.6%)<\/li><li><b>Respiratory:<\/b>Cough (2%)<\/li><li><b>Other:<\/b>Fatigue (4.8%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure (less than 2%), Heart block, Myocardial infarction<\/li><li><b>Hepatic:<\/b>Hepatotoxicity<\/li><\/ul>"},"6":{"id":"180873-s-6","title":"Drug Name Info","sub":{"0":{"id":"180873-s-6-17","title":"US Trade Names","mono":"<ul><li>Cardizem<\/li><li>Cardizem CD<\/li><li>Cartia XT<\/li><li>Dilacor XR<\/li><li>Tiazac<\/li><li>Dilt-CD<\/li><li>Dilt-XR<\/li><li>Diltia XT<\/li><\/ul>"},"2":{"id":"180873-s-6-19","title":"Class","mono":"<ul><li>Benzothiazepine<\/li><li>Calcium Channel Blocker<\/li><li>Cardiovascular Agent<\/li><\/ul>"},"3":{"id":"180873-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"180873-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"180873-s-7","title":"Mechanism Of Action","mono":"Diltiazem hydrochloride is a slow calcium channel blocker that blocks calcium ion influx during depolarization of cardiac and vascular smooth muscle. It decreases peripheral vascular resistance and causes relaxation of the vascular smooth muscle resulting in a decrease of both systolic and diastolic blood pressure.<br\/>"},"8":{"id":"180873-s-8","title":"Pharmacokinetics","sub":[{"id":"180873-s-8-23","title":"Absorption","mono":"<ul><li>Oral, controlled-release capsule: time to peak concentration, 4 h to 6 h<\/li><li>Oral, extended-release capsule: time to peak concentration, 10 h to 14 h<\/li><li>Oral, extended-release, long acting tablet: time to peak concentration, 11 h to 18 h<\/li><li>Bioavailability: (immediate-release), approximately 40%<\/li><li>Bioavailability: (extended-release capsule), approximately 93% to greater than 95%<\/li><li>Bioavailability: (hepatic impairment), increased by 69%<\/li><li>Effect of food: (oral, extended-release capsule, high fat breakfast) brand dependent<\/li><\/ul>"},{"id":"180873-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 305 L to 391 L<\/li><li>Protein binding: 70% to 80%<\/li><\/ul>"},{"id":"180873-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic; cytochrome P450, extensive, deacetylation, N-demethylation, O-demethylation, and conjugation<\/li><li>Metabolites: N-monodesmethyldiltiazem, desacetyldiltiazem, desacetyl-N-monodesmethyldiltiazem, desacetyl-O-desmethyldiltiazem, and desacetyl-N, O-desmethyldiltiazem<\/li><\/ul>"},{"id":"180873-s-8-26","title":"Excretion","mono":"<ul><li>Fecal<\/li><li>Renal: 2% to 4% unchanged<\/li><li>Dialyzable: no (hemodialysis or peritoneal dialysis)<\/li><\/ul>"},{"id":"180873-s-8-27","title":"Elimination Half Life","mono":"<ul><li>(IV), 3.4 h to 4.9 h<\/li><li>(Oral, immediate-release), 3 h to 4.5 h<\/li><li>(Oral, extended-release capsule), 6.5 h (4 h to 9.5 h)<\/li><li>Liver cirrhosis: prolonged<\/li><\/ul>"}]},"9":{"id":"180873-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>may dilute with NS or D5W<\/li><li>(injection) give bolus over 2 min; may repeat in 15 min if inadequate response to first dose<\/li><li>(infusion) start infusion after bolus dose at 5 mg\/hr; may titrate to 15 mg\/hr as needed for up to 24 hours<\/li><\/ul><\/li><li><b>Oral<\/b><br\/><ul><li>Cardizem(R) tablets: Take before meals and at bedtime (4 times daily); swallow whole and do not crush, chew, or split tablets.<\/li><li>Cardizem(R) LA: Take about the same time once daily; swallow whole and do not crush or chew.<\/li><li>Diltia XT(TM), Dilacor XR(R): Take in the morning on empty stomach; swallow whole and do not open, crush, or chew.<\/li><li>Diltiazem Extended-Release: Take twice daily; swallow whole and do not crush or chew.<\/li><li>Taztia XT(TM), Tiazac(R): May sprinkle capsule contents on a spoonful of applesauce, swallow without chewing, and consume immediately; follow by a cool glass of water; use capsule contents\/applesauce mixture immediately and do not store for future use; do not subdivide contents of Tiazac(R) extended-release capsule (Medwatch, 2000)<\/li><\/ul><\/li><\/ul>"},"10":{"id":"180873-s-10","title":"Monitoring","mono":"<ul><li>angina (oral): chest pain<\/li><li>arrhythmias (injection): ECG<\/li><li>hypertension (oral): blood pressure<\/li><li>heart rate, signs and symptoms of cardiac failure<\/li><li>liver function; periodically<\/li><\/ul>"},"11":{"id":"180873-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Intravenous Powder for Solution: 100 MG<\/li><li>Intravenous Solution: 5 MG\/ML<\/li><li>Oral Capsule, Extended Release: 120 MG, 180 MG, 240 MG, 300 MG, 360 MG, 420 MG<\/li><li>Oral Capsule, Extended Release, 12 HR: 60 MG, 90 MG, 120 MG<\/li><li>Oral Capsule, Extended Release, 24 HR: 120 MG, 180 MG, 240 MG, 300 MG, 360 MG, 420 MG<\/li><li>Oral Tablet: 30 MG, 60 MG, 90 MG, 120 MG<\/li><li>Oral Tablet, Extended Release: 180 MG, 240 MG, 300 MG, 360 MG, 420 MG<\/li><\/ul><\/li><li><b>Amerinet Choice Diltiazem Hydrochloride<\/b><br\/>Intravenous Solution: 5 MG\/ML<br\/><\/li><li><b>Cardizem CD<\/b><br\/><ul><li>Oral Capsule, Extended Release: 120 MG<\/li><li>Oral Capsule, Extended Release, 24 HR: 120 MG, 180 MG, 240 MG, 300 MG, 360 MG<\/li><\/ul><\/li><li><b>Cardizem LA<\/b><br\/>Oral Tablet, Extended Release: 120 MG, 180 MG, 240 MG, 300 MG, 360 MG, 420 MG<br\/><\/li><li><b>Cardizem<\/b><br\/>Oral Tablet: 60 MG<br\/><\/li><li><b>Cardizem<\/b><br\/>Oral Tablet: 30 MG, 60 MG, 120 MG<br\/><\/li><li><b>Cardizem SR<\/b><br\/>Oral Capsule, Extended Release, 12 HR: 120 MG<br\/><\/li><li><b>Cartia XT<\/b><br\/>Oral Capsule, Extended Release, 24 HR: 120 MG, 180 MG, 240 MG, 300 MG<br\/><\/li><li><b>Dilacor XR<\/b><br\/>Oral Capsule, Extended Release, 24 HR: 180 MG, 240 MG<br\/><\/li><li><b>Dilt-XR<\/b><br\/>Oral Capsule, Extended Release, 24 HR: 120 MG, 180 MG, 240 MG<br\/><\/li><li><b>Matzim LA<\/b><br\/>Oral Tablet, Extended Release: 180 MG, 240 MG, 300 MG, 360 MG, 420 MG<br\/><\/li><li><b>PremierPro Rx Diltiazem HCl<\/b><br\/>Intravenous Solution: 5 MG\/ML<br\/><\/li><li><b>Taztia XT<\/b><br\/>Oral Capsule, Extended Release, 24 HR: 120 MG, 180 MG, 240 MG, 300 MG, 360 MG<br\/><\/li><li><b>Tiazac<\/b><br\/>Oral Capsule, Extended Release, 24 HR: 120 MG, 180 MG, 240 MG, 300 MG, 360 MG, 420 MG<br\/><\/li><\/ul>"},"12":{"id":"180873-s-12","title":"Toxicology","sub":[{"id":"180873-s-12-31","title":"Clinical Effects","mono":"<b>DILTIAZEM<\/b><br\/>USES: For the treatment of hypertension, dysrhythmias, and stable angina. PHARMACOLOGY: Binds to and antagonizes L-type calcium channels located on all types of muscle cells resulting in relaxation of vascular smooth muscle and arterial vasodilation as well as decreased force of cardiac contraction and decreased heart rate and conduction. TOXICOLOGY: Excessive doses cause bradycardia and conduction delays by suppression of the SA and AV nodes. Decreased contractility is less than that caused by verapamil and more than that caused by nifedipine. Vasodilation is less than that seen after nifedipine overdose. EPIDEMIOLOGY: Common overdose, which may result in significant morbidity and mortality. MILD TO MODERATE TOXICITY: Patients may have asymptomatic bradycardia or mild hypotension which may manifest as dizziness, fatigue, and\/or lightheadedness. SEVERE TOXICITY: Can cause profound bradycardia and dysrhythmias (including complete heart block) and hypotension resulting in cardiogenic shock and end-organ dysfunction including lethargy, syncope, altered mental status, seizures, bowel ischemia, renal failure, metabolic acidosis, acute lung injury, coma, and death.  Hyperglycemia  generally develops in patients with severe poisoning. ADVERSE EFFECTS: COMMON: Minor gastrointestinal effects, headache, and rash are commonly reported. <br\/>"},{"id":"180873-s-12-32","title":"Treatment","mono":"<b>DILTIAZEM<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients who have asymptomatic bradycardia can be admitted and observed with telemetry. Obtain peripheral intravenous access and monitor ECG. Mild hypotension may only require treatment with intravenous fluid administration. MANAGEMENT OF SEVERE TOXICITY: Patients with bradycardia and hypotension require standard ACLS treatment. Place a central line and consider placement of an arterial line. Standard first line treatment includes atropine for bradycardia although in a serious poisoning it is rarely effective. High dose insulin and dextrose have been effective in animal studies and multiple case reports in patients with hypotension refractory to other modalities, and should be considered early in patients with significant hypotension. Use intravenous calcium in severe poisonings although in these cases, beneficial effects of calcium infusion may be very minimal or short-lived. Repeat bolus doses or a continuous intravenous infusion are often needed. Standard vasopressors should be administered to maintain blood pressure. Lipid emulsion has been successful in animal studies and a few case reports of patients with hypotension refractory to other therapies. Intravenous glucagon has been used with variable success. In a patient whose hemodynamic status continues to be refractory despite the treatment described above, extracorporeal membrane oxygenation or cardiopulmonary bypass should be considered. Treat seizures with IV benzodiazepines; barbiturates or propofol may be needed if seizures persist or recur.<\/li><li>Decontamination: PREHOSPITAL: Not recommended because of the potential for abrupt deterioration. HOSPITAL: Because a diltiazem overdose can be life-threatening, all significant ingestions should receive activated charcoal. Patients with altered mental status should be intubated prior to administration. Gastric lavage should be considered in patients with recent large ingestions if the airway is protected. Late gastric lavage may be effective following sustained-release products. Whole bowel irrigation should be considered early for patients who can protect their airway or who are intubated who have ingested sustained-release formulations; it can limit absorption from possible concretions. Whole bowel irrigation should NOT be performed in patients who are hemodynamically unstable.<\/li><li>Airway management: Intubate patients with coma,  mental status depression or significant hemodynamic instability.<\/li><li>Hypotensive episode: Treat initially with fluids (insert a central venous or pulmonary artery catheter to guide fluid therapy if hypotension persists). Consider inserting an arterial line in patients with refractory hypotension. Intravenous calcium, vasopressors, high dose insulin\/dextrose, and glucagon may all be useful for refractory hypotension. Pacemakers (external or internal), intraaortic balloon pump, and cardiopulmonary bypass have been used  in patients refractory to other modalities.<\/li><li>Calcium: Intravenous calcium infusions have been shown to be helpful, although response is often short lived. Optimal dosing is not established; start with an initial IV infusion of about 13 to 25 mEq of calcium (10 to 20 mL of 10% calcium chloride or 30 to 60 mL of 10% calcium gluconate) followed by either repeat boluses every 15 to 20 minutes up to 3 to 4 doses or a continuous infusion starting with 0.5 mEq\/kg\/hr of calcium (0.2 to 0.4 mL\/kg\/hr of 10% calcium chloride or 0.6 to 1.2 mL of 10% calcium gluconate) and titrate as needed. Calcium dosing should be titrated to hemodynamic response rather than serum calcium concentration alone; central venous or pulmonary artery catheters may be useful to guide therapy. Monitor ECG and ionized calcium concentration. Patients with severe overdose have tolerated significant hypercalcemia (up to twice the upper limit of normal) without developing clinical or ECG evidence of hypercalcemia.<\/li><li>Insulin: Administer a bolus of 1 unit\/kg of insulin followed by an infusion of 0.1 to 1 unit\/kg\/hr, titrated to a systolic blood pressure of greater than 90 to 100 mmHg (bradycardia may or may not respond). Reassess every 30 minutes to titrate insulin infusion. Administer dextrose bolus to patients with an initial blood glucose of less than 250 mg\/dL (adults 25 to 50 mL dextrose 50%, children 0.25 g\/kg dextrose 25%). Begin a dextrose infusion of 0.5 g\/kg\/hr in all patients. Monitor blood glucose every 15 to 30 minutes until consistently 100 to 200 mg\/dL for 4 hours, then monitor every hour. Titrate dextrose infusion to maintain blood glucose in the range of 100 to 200 mg\/dL. As the patient improves, insulin resistance abates and dextrose requirements will increase. Supplemental dextrose will be needed for at least several hours after the insulin infusion is discontinued. Administer supplemental potassium initially if patient is hypokalemic (serum potassium less than 2.5 mEq\/L). Monitor serum potassium every 4 hours and supplement as needed to maintain potassium of 2.5 to 2.8 mEq\/L.<\/li><li>Vasopressin: Anecdotal reports suggest that epinephrine, vasopressin, metaraminol, or phenylephrine may occasionally be effective in patients who do not respond to dopamine or norepinephrine.<\/li><li>Fat Emulsion: Lipid emulsion has been successful in animal studies and several case reports of patients with hypotension refractory to other therapies. Administer 1.5 mL\/kg of 20% lipid emulsion over 2 to 3 minutes as an IV bolus, followed by an infusion of 0.25 mL\/kg\/min. If possible, discontinue after 30 to 60 minutes. Longer periods of lipid therapy should be considered if the patient's hemodynamic stability is dependent on continued lipid infusion.<\/li><li>Glucagon: DOSE: ADULT: Optimal dosing in calcium antagonist poisoning is not established. Initially, 3 to 5 mg IV, slowly over 1 to 2 minutes; may repeat treatment with a dose of 4 to 10 mg if there is no hemodynamic improvement within 5 minutes. CHILD: 50 mcg\/kg; repeat doses may be used due to the short half-life of glucagon.<\/li><li>L-Carnitine: L-carnitine may be useful to treat hypotension in the setting of calcium channel blocker overdose. It is not well studied but an animal study and one human case report suggest efficacy. The dose used in the human case report was 6 g IV followed by 1 g IV every 4 hours.<\/li><li>Phosphodiesterase inhibitor: There are case reports where a phosphodiesterase inhibitor (inamrinone, enoximone) appeared to improve blood pressure in patients unresponsive to other modalities.<\/li><li>Monitoring of patient: Monitor vital signs frequently. Institute continuous cardiac monitoring and obtain serial ECGs. In patients with significant hypotension or bradycardia, monitor  serum electrolytes, blood glucose, renal function, arterial or venous blood gas, and urine output. Obtain digoxin level in patients who also have access to digoxin. Monitor cardiac enzymes in patients with chest pain. Serum diltiazem levels are not readily available and not helpful to guide therapy.<\/li><li>Enhanced elimination procedure: Hemodialysis is  not of value because of the high degree of protein binding and a large volume of distribution.<\/li><li>Patient disposition: HOME CRITERIA: According to the AAPCC guidelines, healthy, asymptomatic adults with a single diltiazem ingestion of 120 mg or less immediate-release or a chewed sustained-release formulation, 360 mg or less of a sustained-release formulation, or 540 mg or less extended-release formulation, and 1 mg\/kg or less for a child can be monitored at home. OBSERVATION CRITERIA: Symptomatic patients, those with underlying cardiovascular disease, those taking beta blockers or another cardiodepressant drug, and those with deliberate ingestions should be referred to a health care facility for treatment, evaluation and monitoring. According to the AAPCC guidelines, an adult with an inadvertent single ingestion of diltiazem greater than 120 mg immediate-release or a chewed sustained-release formulation, greater than 360 mg sustained-release formulation, or greater than 540 mg extended-release formulation, and greater than 1 mg\/kg for a child should be referred to a healthcare facility. Patients should be observed for at least 6 hours after ingestion of immediate-release and 18 to 24 hours after ingestion of sustained-release formulations. Patients who develop signs or symptoms of toxicity should be admitted to an intensive care setting. ADMISSION CRITERIA: Any patient with a history of ingestion of sustained release dosage forms or who become symptomatic should be admitted to a monitored setting. CONSULT CRITERIA: Consult a poison center or medical toxicologist in cases of severe poisonings or in cases where there is a history of a large exposure.<\/li><\/ul>"},{"id":"180873-s-12-33","title":"Range of Toxicity","mono":"<b>DILTIAZEM<\/b><br\/>TOXICITY: The following doses are considered to be potentially toxic: an adult with an inadvertent single ingestion of diltiazem greater than 120 mg immediate-release or a chewed sustained-release formulation, greater than 360 mg sustained-release formulation, or greater than 540 mg extended-release formulation, and greater than 1 mg\/kg for a child. THERAPEUTIC DOSE: ADULT: ANGINA: 30 mg four times daily immediate release; 120 to 180 mg once daily, up to a MAX of 540 mg extended release. HYPERTENSION: 120 to 240 mg once daily, up to a MAX of 540 mg once daily extended release.<br\/>"}]},"13":{"id":"180873-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring coordination until drug effects are realized, as drug may cause dizziness.<\/li><li>This drug may cause gingival hyperplasia, headache, or dermatologic reactions such as exfoliative dermatitis (reddened skin, skin peeling\/flaking) or erythema multiforme (flu-like symptoms, spreading red rash, may progress to more severe form with blistering).<\/li><li>Instruct patient to report symptomatic hypotension, bradyarrhythmia, peripheral edema, or syncope.<\/li><li>Advise patient against sudden discontinuation of drug.<\/li><li>This drug is available in multiple brand names with varying properties by brand. Instruct patient to follow administration instructions specific to the prescribed brand with regards to meals and timing.<\/li><li>Patient should avoid concomitant use of beta-blockers or digitalis during drug therapy, unless otherwise directed by healthcare professional.<\/li><li>Patient should not drink alcohol while taking this drug.<\/li><\/ul>"}}}